Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Meridian Health
mi
from
Neptune, NJ
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Meridian Health
mi
from
Neptune, NJ
Click here to add this to my saved trials
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Atlantic Respiratory Institute
mi
from
Summit, NJ
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Atlantic Respiratory Institute
mi
from
Summit, NJ
Click here to add this to my saved trials
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Radiology Associates of Albuquerque
mi
from
Albuquerque, NM
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Radiology Associates of Albuquerque
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Status: Enrolling
Updated:  12/31/1969
bioAffinity Technologies
mi
from
San Antonio, TX
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Status: Enrolling
Updated: 12/31/1969
bioAffinity Technologies
mi
from
San Antonio, TX
Click here to add this to my saved trials
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
Status: Enrolling
Updated:  12/31/1969
Memorial Healthcare System
mi
from
Hollywood, FL
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
Status: Enrolling
Updated: 12/31/1969
Memorial Healthcare System
mi
from
Hollywood, FL
Click here to add this to my saved trials
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
Status: Enrolling
Updated:  12/31/1969
Ochsner Medical Center
mi
from
New Orleans, LA
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
Status: Enrolling
Updated: 12/31/1969
Ochsner Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
A Phase I/II Study of Tergenpumatucel-L (HyperAcute Lung) an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
A Phase I/II Study of Tergenpumatucel-L (HyperAcute Lung) an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
A Phase I Study of a HER-2/Neu Peptide Based Vaccine With GM-CSF as an Adjuvant in Patients With Advanced Stage HER-2/Neu Expressing Cancers
Status: Enrolling
Updated:  12/31/1969
University of Washington School of Medicine
mi
from
Seattle, WA
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
A Phase I Study of a HER-2/Neu Peptide Based Vaccine With GM-CSF as an Adjuvant in Patients With Advanced Stage HER-2/Neu Expressing Cancers
Status: Enrolling
Updated: 12/31/1969
University of Washington School of Medicine
mi
from
Seattle, WA
Click here to add this to my saved trials
Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I Trial of Farnesyltransferase Inhibitor, R115777 (NSC # 702818) and Radiotherapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I Trial of Farnesyltransferase Inhibitor, R115777 (NSC # 702818) and Radiotherapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Development and Feasibility Testing of a Lung Cancer Screening Decision Aid
Development and Feasibility Testing of a Lung Cancer Screening Decision Aid
Status: Enrolling
Updated:  12/31/1969
University of Miami (FL)
mi
from
Miami, FL
Development and Feasibility Testing of a Lung Cancer Screening Decision Aid
Development and Feasibility Testing of a Lung Cancer Screening Decision Aid
Status: Enrolling
Updated: 12/31/1969
University of Miami (FL)
mi
from
Miami, FL
Click here to add this to my saved trials
Development and Feasibility Testing of a Lung Cancer Screening Decision Aid
Development and Feasibility Testing of a Lung Cancer Screening Decision Aid
Status: Enrolling
Updated:  12/31/1969
University of Kentucky
mi
from
Lexington, KY
Development and Feasibility Testing of a Lung Cancer Screening Decision Aid
Development and Feasibility Testing of a Lung Cancer Screening Decision Aid
Status: Enrolling
Updated: 12/31/1969
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Once Weekly Radiation for Lung Cancer With Chemotherapy
Combination of Weekly Radiation and Docetaxel for Locally Advanced Non Small Cell Lung Cancer: A Feasibility Study
Status: Enrolling
Updated:  11/18/2005
Cancer Center and Mobile Infirmary Hospital
mi
from
Mobile, AL
Once Weekly Radiation for Lung Cancer With Chemotherapy
Combination of Weekly Radiation and Docetaxel for Locally Advanced Non Small Cell Lung Cancer: A Feasibility Study
Status: Enrolling
Updated: 11/18/2005
Cancer Center and Mobile Infirmary Hospital
mi
from
Mobile, AL
Click here to add this to my saved trials
Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy
Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study
Status: Enrolling
Updated:  11/21/2005
Providence Hospital,
mi
from
Mobile, AL
Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy
Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study
Status: Enrolling
Updated: 11/21/2005
Providence Hospital,
mi
from
Mobile, AL
Click here to add this to my saved trials
Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy
Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study
Status: Enrolling
Updated:  11/21/2005
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy
Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study
Status: Enrolling
Updated: 11/21/2005
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Defining the Interaction of Docetaxel and Lonafarnib in Patients With Advanced Malignancies
Status: Enrolling
Updated:  2/6/2006
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Defining the Interaction of Docetaxel and Lonafarnib in Patients With Advanced Malignancies
Status: Enrolling
Updated: 2/6/2006
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Use of Harmonic Scalpel to Decrease Lymphatic and Chest Tube Drainage After Lymph Node Dissection With Lobectomy.
Use of Harmonic Scalpel to Decrease Lymphatic and Chest Tube Drainage After Lymph Node Dissection With Lobectomy. A Single Center Prospective Randomized Controlled Study.
Status: Enrolling
Updated:  1/10/2008
Sentara Norfolk General Hospital/Sentara Heart Hospital
mi
from
Norfolk, VA
Use of Harmonic Scalpel to Decrease Lymphatic and Chest Tube Drainage After Lymph Node Dissection With Lobectomy.
Use of Harmonic Scalpel to Decrease Lymphatic and Chest Tube Drainage After Lymph Node Dissection With Lobectomy. A Single Center Prospective Randomized Controlled Study.
Status: Enrolling
Updated: 1/10/2008
Sentara Norfolk General Hospital/Sentara Heart Hospital
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection
Phase III Study of Preoperative Amiodarone for Prevention of Atrial Fibrillation After Lung Resection
Status: Enrolling
Updated:  5/5/2008
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection
Phase III Study of Preoperative Amiodarone for Prevention of Atrial Fibrillation After Lung Resection
Status: Enrolling
Updated: 5/5/2008
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent Chemoradiation (ChemoRT) for Non-Small Cell Lung Cancer (NSCLC)
0516 GCC: Stereotactic Body Radiation Therapy As A Boost After Definitive Treatment With Concurrent Chemoradiation In Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/7/2009
University of Maryland, Baltimore
mi
from
Baltimore, MD
Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent Chemoradiation (ChemoRT) for Non-Small Cell Lung Cancer (NSCLC)
0516 GCC: Stereotactic Body Radiation Therapy As A Boost After Definitive Treatment With Concurrent Chemoradiation In Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/7/2009
University of Maryland, Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
NNAL Clearance in Hair and Urine
Elimination of NNAL and Cotinine From Hair and Urine
Status: Enrolling
Updated:  3/17/2009
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
NNAL Clearance in Hair and Urine
Elimination of NNAL and Cotinine From Hair and Urine
Status: Enrolling
Updated: 3/17/2009
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
A Dose Escalation Study of Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/13/2009
Yale University School of Medicine
mi
from
New Haven, CT
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
A Dose Escalation Study of Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/13/2009
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
A Phase II Feasibility Study of Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate Followed ny Adjuvant ALIMTA/Cisplatin
Status: Enrolling
Updated:  10/30/2009
Brigham and Women's Hosp
mi
from
Boston, MA
Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
A Phase II Feasibility Study of Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate Followed ny Adjuvant ALIMTA/Cisplatin
Status: Enrolling
Updated: 10/30/2009
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
A Phase II Feasibility Study of Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate Followed ny Adjuvant ALIMTA/Cisplatin
Status: Enrolling
Updated:  10/30/2009
Dana-Farber Cancer Institute
mi
from
Boston, MA
Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
A Phase II Feasibility Study of Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate Followed ny Adjuvant ALIMTA/Cisplatin
Status: Enrolling
Updated: 10/30/2009
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
A Phase I Trial of Extrapleural Pneumonectomy/Pleurectomy Decortication, Intrathoracic/Intraperitoneal Hyperthermic (IOHC) Cisplatin and Gemcitabine With Intravenous Amifostine and Sodium Thiosulfate Cytoprotection for Patients With Resectable Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/30/2009
Brigham and Women's Hosp
mi
from
Boston, MA
Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
A Phase I Trial of Extrapleural Pneumonectomy/Pleurectomy Decortication, Intrathoracic/Intraperitoneal Hyperthermic (IOHC) Cisplatin and Gemcitabine With Intravenous Amifostine and Sodium Thiosulfate Cytoprotection for Patients With Resectable Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/30/2009
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Investigating the Improvement in 4D CT Images Using AV Biofeedback
Investigating the Improvement in 4D CT Images Using Audiovisual Biofeedback: An Intra-fraction and an Inter-fraction Evaluation.
Status: Enrolling
Updated:  11/16/2009
University of Maryland
mi
from
Baltimore, MD
Investigating the Improvement in 4D CT Images Using AV Biofeedback
Investigating the Improvement in 4D CT Images Using Audiovisual Biofeedback: An Intra-fraction and an Inter-fraction Evaluation.
Status: Enrolling
Updated: 11/16/2009
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging
Status: Enrolling
Updated:  3/25/2010
GE Healthcare Office
mi
from
Princeton, NJ
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging
Status: Enrolling
Updated: 3/25/2010
GE Healthcare Office
mi
from
Princeton, NJ
Click here to add this to my saved trials
Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors
Investigating the Feasibility of Using Real-time Cine-MRI for Treating Moving and Deforming Tumors
Status: Enrolling
Updated:  6/24/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors
Investigating the Feasibility of Using Real-time Cine-MRI for Treating Moving and Deforming Tumors
Status: Enrolling
Updated: 6/24/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma
Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma
Status: Enrolling
Updated:  7/2/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma
Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma
Status: Enrolling
Updated: 7/2/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
A Multi-Center Phase 1b Pharmacokinetic and Radiation Dosimetry Study Evaluating 99mTc-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  8/4/2010
University of Chicago
mi
from
Chicago, IL
Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
A Multi-Center Phase 1b Pharmacokinetic and Radiation Dosimetry Study Evaluating 99mTc-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 8/4/2010
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
A Multi-Center Phase 1b Pharmacokinetic and Radiation Dosimetry Study Evaluating 99mTc-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  8/4/2010
Mayo Clinic, Division of Nuclear Medicine
mi
from
Rochester, MN
Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
A Multi-Center Phase 1b Pharmacokinetic and Radiation Dosimetry Study Evaluating 99mTc-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 8/4/2010
Mayo Clinic, Division of Nuclear Medicine
mi
from
Rochester, MN
Click here to add this to my saved trials
Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
A Multi-Center Phase 1b Pharmacokinetic and Radiation Dosimetry Study Evaluating 99mTc-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  8/4/2010
Montefiore Medical Center
mi
from
Bronx, NY
Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
A Multi-Center Phase 1b Pharmacokinetic and Radiation Dosimetry Study Evaluating 99mTc-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 8/4/2010
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated:  9/16/2010
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated: 9/16/2010
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated:  9/16/2010
University of California, San Francisco
mi
from
San Francisco, CA
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated: 9/16/2010
University of California, San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated:  9/16/2010
National Jewish Health
mi
from
Denver, CO
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated: 9/16/2010
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated:  9/16/2010
Georgetown University School of Medicine
mi
from
Washington,
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated: 9/16/2010
Georgetown University School of Medicine
mi
from
Washington,
Click here to add this to my saved trials
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated:  9/16/2010
Feinberg School of Medicine, Northwestern University
mi
from
Chicago, IL
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated: 9/16/2010
Feinberg School of Medicine, Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated:  9/16/2010
University of Illinois at Chicago, College of Medicine
mi
from
Chicago, IL
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated: 9/16/2010
University of Illinois at Chicago, College of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated:  9/16/2010
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated: 9/16/2010
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated:  9/16/2010
Boston University School of Medicine
mi
from
Boston, MA
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated: 9/16/2010
Boston University School of Medicine
mi
from
Boston, MA
Click here to add this to my saved trials
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated:  9/16/2010
University of Michigan Medical School
mi
from
Ann Arbor, MI
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated: 9/16/2010
University of Michigan Medical School
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated:  9/16/2010
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated: 9/16/2010
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated:  9/16/2010
Medical University of South Carolina
mi
from
Charleston, SC
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated: 9/16/2010
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated:  9/16/2010
University of Texas Medical School in Houston
mi
from
Houston, TX
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Status: Enrolling
Updated: 9/16/2010
University of Texas Medical School in Houston
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer
Outcome Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage NSCLC
Status: Enrolling
Updated:  11/8/2010
Weill-Cornell Medical College
mi
from
New York, NY
A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer
Outcome Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage NSCLC
Status: Enrolling
Updated: 11/8/2010
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated:  11/23/2010
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated: 11/23/2010
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated:  11/23/2010
Mercy Research Institute
mi
from
Miami, FL
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated: 11/23/2010
Mercy Research Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated:  11/23/2010
University of Miami
mi
from
Miami, FL
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated: 11/23/2010
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated:  11/23/2010
Rush University Medical Center
mi
from
Chicago, IL
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated: 11/23/2010
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated:  11/23/2010
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated: 11/23/2010
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated:  11/23/2010
Massachusetts General Hospital
mi
from
Boston, MA
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated: 11/23/2010
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated:  11/23/2010
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Status: Enrolling
Updated: 11/23/2010
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials